Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bear 1X Shares

19.23
0.0000
Volume:- -
Turnover:- -
Market Cap:2.40M
PE:- -
High:19.23
Open:19.23
Low:19.23
Close:19.23
52wk High:27.16
52wk Low:16.40
Shares:125.00K
Float Shares:125.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:1.01
Dividend Rate:5.26%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

1 Weight Loss Drugs Effective Even at Low Starter Doses

Reuters
·
28 mins ago

Dow Jones Top Company Headlines at 5 PM ET: FTC Files Lawsuit Alleging Amazon Deceived Advertisers | State ...

Dow Jones
·
1 hour ago

Ataibeckley - Hart-Scott-Rodino Waiting Period for Merger with Eli Lilly Expired on Aug 28, 2026 - SEC Filing

THOMSON REUTERS
·
2 hours ago

Sector Update: Healthcare Stocks Decline Monday Afternoon

MT Newswires Live
·
5 hours ago

Moderately bullish activity in Eli Lilly with shares down 1.26%

TIPRANKS
·
6 hours ago

Top Midday Stories: Stocks Fall, Oil Rises Amid Renewed Fighting in Middle East; Utility Shares Fall After California Wildfire Legislation

MT Newswires Live
·
Yesterday

Dow Jones Top Company Headlines at 11 am ET: GameStop Sees Higher Profit as eBay Investment Offsets Lower Sales | SLB ...

Dow Jones
·
Yesterday

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Yesterday

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Yesterday

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Yesterday

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Yesterday

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Yesterday

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Yesterday

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Yesterday

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Yesterday

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Yesterday

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Yesterday

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Yesterday

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29